ArticleBMC complementary medicine and therapies2026
Indonesian stingless bee propolis extract attenuates hepatic inflammation following a chronic high-saturated fat diet.
Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic syndromes, including obesity, dyslipidemia, and diabetes mellitus, can exacerbate inflammation-induced liver damage, which is associated with high-fat diets (HFD) and sedentary lifestyles. The substantial hypolipidemic and anti-inflammatory properties of propolis extract can potentially reduce hepatic inflammation and prevent the progression of liver damage. This study aims to investigate the role of Indonesian propolis extract in reducing hepatic inflammation after dyslipidemia and hyperglycemia.
methodsThe experiment started with feeding HFD to the rats for 12 weeks, then a daily dosage of 300 mg/kg BW of propolis extract was administered via gavage for 9 weeks. Body weight, liver index, and blood biochemical analysis were conducted to determine the pharmacodynamic evaluation of propolis extract. The expression of inflammatory cytokines was investigated in the liver tissue. The correlation and regression analysis assessed the relationship between dyslipidemia, hyperglycemia, and hepatic inflammation.
resultsNine weeks of propolis extract supplementation significantly decreased body weight and liver index. Propolis also improves blood profile by reducing cholesterol, triglycerides, LDL-C, and glucose levels and increasing HDL-C levels. The expression of hepatic inflammatory cytokines such as IL-1β, IL-6, and TNF-α was decreased in the HFD group after propolis administration. A significant moderate to strong correlation (0.56–0.94) was found between the lipid profile, glucose levels, and hepatic inflammation. The lipid profile represented approximately 84.6%, 49.9%, and 68.7% of the hepatic inflammatory cytokine expression variation of IL-1β, IL-6, and TNF-α.
conclusionBased on current evidence, Indonesian propolis alleviated hepatic inflammation by improving dyslipidemia and hyperglycemia after a prolonged high-fat diet in vivo. Therefore, further clinical studies are warranted to substantiate its complementary role in metabolic or inflammatory conditions. CLINICAL TRIAL NUMBER: Not Applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.